At a glance
- Originator Meiji Seika Kaisha
- Class Macrocyclic compounds
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 25 May 2000 Preclinical development for Mycoses in Japan (Unknown route)